Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
OptiBiotix signs partnership with India's Dr Morepen
(Sharecast News) - Life science company OptiBiotix Health announced the signing of a partnership agreement with Dr Morepen on Wednesday, for the distribution of SlimBiome products in India under the Dr Morepen brand. The AIM-traded firm said Dr Morepen is a wholly-owned subsidiary of Morepen Laboratories, which it described as a prominent Indian pharmaceutical company listed on the Indian Stock Exchange.
With a workforce of over 2,300 employees, Morepen Laboratories has a product portfolio of more than 800 items distributed in over 82 countries.
Established in 2001, Dr Morepen had emerged as a trusted brand in India with a mission to empower consumers to take charge of their health and wellbeing.
Leveraging its network, Dr Morepen has direct access to over 200,000 pharmacies throughout India and indirect access to another 300,000.
The SlimBiome products would be available for purchase both online and in-store, and through direct channels to physicians across the country.
OptiBiotix said the collaboration with Dr Morepen was a significant advancement in making innovative health solutions more accessible to the Indian market.
"We are pleased to announce this agreement with Morepen, a well-known and trusted supplier to pharmacies, physicians, and retail customers across India," said chief executive officer Stephen O'Hara.
"Morepen brings an extensive sales team with experience of highly differentiated scientific products and countrywide access to a network of around 500,000 pharmacies across India.
"Based on current forecasts, the directors anticipate this agreement could contribute in the region of £6m to £7m revenue per annum in the next four to five years."
At 1404 GMT, shares in OptiBiotix Health were up 7% at 25.68p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.